within Pharmacolibrary.Drugs.ATC.C;

model C01DA38
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0011666666666666668,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01DA38</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tenitramine is a synthetic antianginal and vasodilator agent belonging to the class of nitrates, previously considered for the treatment of angina pectoris and heart conditions. It is not currently approved or in clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical healthy adult, as no published sources exist reporting pharmacokinetics of tenitramine.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=\"https://doi.org/10.1007/s40261-015-0320-8\">10.1007/s40261-015-0320-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26334726/\">https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Freedman, MD, &amp; Somberg, JC (1991). Pharmacology and pharmacokinetics of amiodarone. <i>Journal of clinical pharmacology</i> 31(11) 1061–1069. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1991.tb03673.x\">10.1002/j.1552-4604.1991.tb03673.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1753010/\">https://pubmed.ncbi.nlm.nih.gov/1753010</a></p></li><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2021). Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. <i>Pharmaceutical research</i> 38(8) 1345–1356. DOI:<a href=\"https://doi.org/10.1007/s11095-021-03078-w\">10.1007/s11095-021-03078-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34341958/\">https://pubmed.ncbi.nlm.nih.gov/34341958</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01DA38;
